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DNA flow cytometry of breast cancer fine needle aspirates
Sir - There are a number of points which I believe should be
raised with regard to the article by Mullen and Miller (1989)
on DNA flow cytometry of breast cancer fine needle
aspirates. First, I would point out that the authors have
omitted to reference previous contributions on the same topic
(Spyratos et al., 1987; Remvikos et al., 1988a, Briffod et al.,
1989). Second, as a cytometrist, I believe that data file histo-
grams should be presented (rather than redrawn ones) as
these usually contain extensive information on the quality of
the preparations (baseline, noise, skewed peaks, aggregates).
Third, the method of calculation of S-phase values should
always be stated.
The most important weakness of the article is the
definition of the variations on the histograms. For instance, a
modification of more than 5% in DNA index is considered
significant, where the standard deviation inherent in the
method of calculation (internal standard) is of 4%. From a
statistical point of view, a threshold of at least twice the
standard deviation should be used, i.e. 8%. Incidentally, the
committee on nomenclature of flow cytometry published its
recommendations in 1984 (Hiddeman et al., 1984), stipulating
that animal cells should definitely not be used as calibration
standards. To my knowledge, these recommendations have
been recognised by the Society of Analytical Cytology and
are followed by most cytometrists. As for the modifications
of cell populations, this is a very delicate point that should
be treated with much caution. A variation in the proportion
of the diploid cells could first of all be due to the presence of
a variable contingent of normal cells (lymphoid infiltrate for
example). Therefore, a precise score of the normal cells must
be established on control smears before a threshold of 10%
for a substantial difference between duplicate analyses can be
validated. Breast cancers are heterogeneous. This has been
shown by Auer et al. (1980), but also by our comparison of
FCM and cytogenetics for the same tumour (Remvikos et al.,
1988b), with sometimes a paradiploid and an aneuploid clone
being simultaneously present. Variations in the proportions
of the different cell populations in repeated samplings are
therefore to be expected.
A final point I wish to make concerns the usefulness of
iterative FNA in the assessment of response to treatment. By
analogy with in vitro experiments, modifications in the cell
cycle distribution are primarily to be expected (for instance
accumulation of cells in S or G2M). This was shown in the
pioneering work of Vindelov et al. (1982) and has been
confirmed for breast cancers (Spyratos et al., 1988; Remvikos
et al., 1988c).
DNA flow cytometry (FCM) is a promising method in
clinical oncology, in particular because of the possibility of
measuring DNA index and S-phase fractions (Kalionemi et
al., 1988). It was recently shown that DNA-ploidy and S-
phase fraction are significantly related to response to
cytotoxic chemotherapy (Briffod et al., 1989; Remvikos et al.,
1989). I believe that the article by Mullen and Miller can
only bring unjustified confusion to the minds of clinicians
who may be interested in FCM.
Yours etc.,
Y. Remvikos
Laboratory of Physiopathology,
Institut Curie,
26 rue d'Ulm,
75231 Paris, France.
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Response to the letter from Dr Remvikos
Sir - The letter from Dr Remvikos makes a number of
criticisms of our paper (Mullen & Miller, 1989) which we feel
are worth defending. With regard to the originality of the
article and the possible omission of other work (Spyratos et
al., 1987; Remvikos et al., 1988; Briffod et al., 1989), we feel
our work is indeed original. Both Spyratos and Remvikos,
while commenting on the clinical importance of sequential
FNAs for flow cytometric DNA analysis, do not provide any
data pertaining to reproducibility and variability of such
serial FNAs, although both studies, like our own, do provide
data comparing FNAs with surgically excised biopsies. The
third study (Briffod et al., 1989) was not in print when our
manuscript was accepted for publication, hence its exclusion
(along with Remvikos et al., 1989).